medigraphic.com
ISSN 0188-2198 (Print)

2002, Number 2

<< Back

Rev Mex Cardiol 2002; 13 (2)

Myths rupture and realities consolidation. Preliminary analysis of the Heart Protection Study

Luque CAF, Eguia BA

Language: Spanish
References: 18
Page: 67-70
PDF size: 67.65 Kb.


Text Extraction

No abstract


REFERENCES

  1. Virchow R. Cellular pathology. London, John Churchill 1858.

  2. D´Agostino RB, Russel MW, Huse DM et al. Primary and subsequent coronary risk appraisal: New results from The Framinham Study. Am Heart J 2000; 139: 272-281

  3. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple risk factor intervention trial research group. JAMA. 1982; 248(12): 1465-77.

  4. Martin MJ, Hulley, SB, Browner, WS. Serum cholesterol, blood pressure and mortality; implications from a cohort of 361,662 men. Lancet 1986: ii: 933-936.

  5. Heart and stroke facts: 1996 Statistical supplement. American Heart Association 1995.

  6. Encuesta Nacional de Enfermedades Crónicas 3a. Edición julio 1996, Dirección General de Epidemiología. Secretaría de Salud.

  7. Heart and stroke facts: 2002 Statistical update, American Heart Association.

  8. Roberts WC. Am J Cardiol From the Editor, 1996.

  9. Kjekshus J, Pedersen TR. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvstatin Survival Study 4S. Lancet 1994; 344: 1383-1389.

  10. Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghhfelt T, Kjekshus J et al. Reducing the risk of coronary events: evidence from Scandinavian Simvastatin Survival Study. Am J Cardiol 1995; 76: 64C-68C.

  11. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.

  12. Sacks FM, Pffefer MA, Moye LA, Roleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.

  13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCaps. JAMA 1998; 279: 1615-1622.

  14. MRC/BHF Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: 725-741.

  15. Cobo AC. Ácido acetilsalicílico y vitamina E en la prevención de enfermedades cardiovasculares. Rev Mex Cardiol 2001; 12(3): 128-133.

  16. Davis L. Custom-fit vitamins. Reader’s Digest 2001; 159(955): 88-95.

  17. Jialal D, Stein D, Balis S, Grundy M, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933.

  18. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, the Air Force/Texas coronary atherosclerosis prevention study investigators et al measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344: 1959-1965.




2020     |     www.medigraphic.com